Pharmaceuticals
MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients
NYON, Switzerland, Nov. 25, 2020 /PRNewswire/ -- MedAlliance has announced completion of patient enrolment in theISABELLA Clinical Trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of dysfunctional AV fistulas in end-stage renal failure patients undergoing hemodialysis. SE...
2020-11-25 08:00
2502
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire/ -- RedHill
Biopharma Ltd.
2020-11-25 07:00
2765
Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
BARCELONA, Spain, Nov. 25, 2020 /PRNewswire/ -- AlmirallShare
2020-11-25 06:00
5696
China Biologic Reports Financial Results for the Third Quarter of 2020
BEIJING, Nov. 24, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the third quarter of 2020. Third Quarter...
2020-11-25 05:30
12097
The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets
RDIF continues expanding existing agreements with international manufacturing partners to produce the vaccine for more than 500 million people in 2021 MOSCOW, Nov. 25, 2020 * The cost of one dose of the Sputnik V vaccine for international markets will be less than$10. Sputnik V is a two dose ...
2020-11-25 04:38
1391
Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose
MOSCOW, Nov. 24, 2020 /PRNewswire/ -- * The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose). * Calculation was based on the analysis of data on volunteers (n = 18,794) ...
2020-11-24 22:14
1439
OliPass Announces Formation of Scientific Advisory Board of Pioneers in Sodium Ion Channellopathy and Pain
SEOUL, South Korea, Nov. 24, 2020 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to commission a Scientific Advisory Board ("SAB") of key experts in sodium ion channelopathy and pain. The SAB will advise OliPass on th...
2020-11-24 22:00
1954
New Centre for Medicines Research (CMR) Clinical Factbook From Clarivate Highlights Increasing Cost and Complexity of Phase II Trials
Pharmaceutical clinical industry report highlights factors impacting volume, cost and duration of Phase II trials LONDON, Nov. 24, 2020 /PRNewswire/ -- Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced t...
2020-11-24 16:05
7498
Koru Lifescience preparing to send drug compounds to preclinical and clinical trials based on their study for Covid-19
AUCKLAND, New Zealand, Nov. 24, 2020 /PRNewswire/ -- Koru Lifescience, drug discovery, and advanced formulation research laboratory inAuckland, New Zealand , has identified several known drug compounds of value in their study for a treatment of Covid-19. The study reports shall be published after ...
2020-11-24 04:35
1044
3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212
SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company"), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), the Company's partner, has commenced the phase III clinical program of a combination therapy involving SEL...
2020-11-23 21:28
10414
Tony Blair Institute and Oracle Launch Africa Vaccine Management in the Cloud
LONDON and REDWOOD SHORES, Calif., Nov. 23, 2020 /PRNewswire/ -- The Tony Blair Institute (TBI) and Oracle have brought cloud technology toAfrica to manage public health programs. Initially,Ghana, Rwanda, and Sierra Leone will use the newOracle Health Management System to create electronic health...
2020-11-23 21:05
5088
GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer's Disease trial
SEOUL, Nov. 23, 2020 /PRNewswire/ -- GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association's Fall Conference from a Phase II trial in Alzheimer's disease of lead candi...
2020-11-23 20:00
2250
Fresenius Kabi and ASPEN partner for an expert interview series on omega-3 fatty acid containing parenteral nutrition
BAD HOMBURG, Germany, Nov. 23, 2020 /PRNewswire/ -- Evidence indicates that omega-3 (ω-3) fatty acid containing parenteral nutrition (PN) improves clinical outcomes compared with standard PN in adult patients,1 underlining its role in today's hospitals and clinics. To support continuous health ca...
2020-11-23 19:00
1794
Innovent Announces NMPA Granted New Indication Approval for SULINNO® (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2020-11-23 18:34
9526
Ascentage Pharma Receives Approvals for Two Phase Ib/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenström Macroglobulinemia and Multiple Myeloma in China
SUZHOU, China and ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Eva...
2020-11-23 18:32
1883
ESMO ASIA Congress 2020 | CStone Pharmaceuticals announces the results of GEMSTONE-302, Sugemalimab has the potential to provide a new treatment option for patients with advanced NSCLC
SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today announced that positive clinical data based on a pre-p...
2020-11-23 09:30
3697
Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodies
DAEJEON, South Korea and CASTRES, France, Nov. 23, 2020 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have announced their plans to form a strategic partnership in the field of immuno-oncology research. The decision has been acknowle...
2020-11-23 09:00
2309
Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020
SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2020-11-23 08:00
5835
Novel Antioxidant Seen as an Effective Strategy for Peripheral Artery Disease
OMAHA, Ne., Nov.20, 2020 /PRNewswire/ -- Researchers within the School of Health and Kinesiology at theUniversity of Nebraska at Omaha (UNO) have found that a novel antioxidant can provide a number of health benefits for individuals with peripheral artery disease. The antioxidant specifically ta...
2020-11-20 23:07
2342
Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange
HONG KONG, Nov. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leader in discovery, development and commercialization of innovative cancer medicines, today announced that the company was officially listed and it's shares commenced trading on the Main Board...
2020-11-20 21:09
13019
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
